Atherosclerosis-related deaths from heart attacks and strokes remain leading causes of global mortality, despite the use of lipid-lowering statins. Thus, there is an urgent need to develop additional therapies.
Introduction
Atherosclerosis is a chronic inflammatory disease initiated by lipid entry into the arterial wall. Immune cells drive the development, acceleration, and propagation of atherosclerotic lesions that lead to formation of vulnerable plaques by complex interactions involving both adaptive and innate immune mechanisms, with lymphocytes activated by antigen-presenting dendritic cells, secreting pro-atherogenic factors including inflammatory cytokines and cytotoxins 1 and macrophages activated via innate mechanisms or cytokines such as IL-4 increasing their expression of MMPs. 2 Vulnerable plaques are characterized by large necrotic cores. 3 Rupture of vulnerable plaques causes thrombotic occlusion of coronary and carotid arteries resulting in myocardial infarctions and strokes 4 that together remain leading causes of global mortality. Current atherosclerosis management primarily aims to lower plasma LDL levels through statin medication and lifestyle changes with secondary measures to prevent platelet aggregation and hypertension 5 without targeting inflammation. The observations that cholesterol-lowering drugs, statins, reduce the risk of cardiovascular events by only one-third of patients with atherosclerosis, 6 and evidence that inflammation is crucial for the development of cardiovascular events 7 have stimulated the development of new therapeutic strategies that target inflammation and the immune system in atherosclerosis management. 8 Experimental therapeutic studies that target inflammation in atherosclerosis include the development of vaccines, 9 depletion of pathogenic immune cells, 10 -13 and expansion of atheroprotective immune cells. 14, 15 NKT cells express NK markers and TCR that recognize lipid antigens presented by the MHC class I-like molecule CD1d on antigenpresenting cells. CD1d-restricted NKT cells are classified into two types: Type I, expressing invariant TCR and Type II, expressing diverse TCR. The TCR of invariant NKT cells has TCRa chain (Va14-Ja18) paired with TCRb chain of Vb8.2, Vb7, or Vb2. Two major subsets of Type 1 invariant NKT cells are distinguished by CD4 and CD8 expression into CD4
1 and CD4/CD8 double negative (DN) subsets. In mice, NKT cells are found at highest frequency in the liver (10 -30% of liver lymphocytes), and at lower frequencies (,2.5%) in other lymphoid organs. 16, 17 Activated NKT cells modulate immune responses in transplantation, oncology, autoimmunity, infection, and inflammation. 18 CD1d-restricted Type I and Type II NKT cells have differential recognition of lipid antigens. Type I NKT cells are potently stimulated by a-galactosylceramide (aGalCer) derived from marine sponge. 19 In contrast, Type II NKT cells respond to sulfatide, a sulfated form of b-galactosylceramide (bGalCer). 20 NKT cells are present in human and mouse atherosclerotic lesions. 21 -23 Mice rendered NKT cell deficient by knocking out CD1d gene have reduced atherosclerosis, 24 indicating that NKT cells promote atherosclerosis development. Type 1 NKT cells are pro-atherogenic as NKT cell activation by injecting aGalCer-aggravated atherosclerosis. 25 It has been further confirmed as atherosclerosis was reduced in Ja18 
Endpoint tissue collection
At the end of experiment, livers were collected for NKT and non-NKT lymphocyte analysis. Aortic sinuses were dissected, embedded in OCT, and kept at 2808C. Spleen and aortic arches were snap-frozen and kept at 2808C. Plasmas separated from whole blood collection were kept at 2808C.
Liver lymphocyte isolation
Livers collected in 1× PBS containing 2% fetal bovine serum (FBS) and 2 mM ethylenediaminetetraacetic acid (EDTA) were mashed using a plunger and metal sieve (200 mm wire mesh) and washed in 50 mL of 1× PBS containing 2% FBS and 2 mM EDTA twice with centrifugation at 500 g for 5 min at 48C. Cell pellets resuspended in 25 mL of isotonic Percoll (#17-0891-01, GE Healthcare, Piscataway, NJ, USA) were centrifuged at 750 g for 20 min at room temperature. Floating hepatocytes were removed and cell pellets containing lymphocytes and red blood cells were treated with red cell lysis buffer (0.155 M NH 4 Cl, 0.01 M KHCO 3 , and 0.1 mM EDTA). Liver lymphocytes were then collected after centrifugation at 300 g for 10 min at 48C.
Assessment of liver lymphocytes
All liver lymphocytes were stained with phycoerythrin (PE)-conjugated CD19 (BD Biosciences), allophycocyanin (APC)-conjugated CD4 antibody (BD Biosciences, San Diego, CA, USA), pacific blue-conjugated CD8a antibody (BD Biosciences), R-PE with cyanine dye (Cy7; PE-Cy7)-conjugated anti-NK1.1 antibody (BD Biosciences), and FITC-conjugated anti-TCRb antibody (BD Biosciences) as described. 12 In some experiment, PEconjugated CD1d tetramer (a gift from Dale Godfrey, Melbourne University) and FITC-conjugated anti-CD3 antibody (BD Biosciences) were utilized. Data were acquired in FACSCanto TM II flow cytometer (BD Biosciences) and analysed by the FACS Diva software (BD Biosciences).
Section of aortic sinus and analysis of stained sections
Cryostat sections (6 mm) of aortic sinuses were collected on 14 sequential slides containing three sections per slide. One slide was used for each immunological or histological staining and were analysed by different laboratory personnel.
Assessment of atherosclerosis
Frozen sections of 6 mm thick aortic sinuses were stained with Oil Red-O (Sigma, St Louis, MO, USA). Total lesion areas defined as intimal atherosclerotic areas and lesion lipid accumulation areas identified by ORO-staining areas were measured using the Optimas software as described. 1 
Assessment of macrophage and lymphocyte accumulation
Immunohistochemical analysis was carried out on frozen sections of aortic atherosclerotic lesions using anti-CD68, anti-CD4, and anti-CD8 antibodies (BD Biosciences). Macrophages were identified and counted as haematoxylin-stained nuclei associated with CD68 staining. CD4
+ and CD8 + T cells were also similarly counted under the microscope and adjusted according to total intimal lesion area as described. 1 Aortic sinus lesions were also immunohistologically stained for B cells using anti-CD19 antibody (BD Biosciences), counted, and presented as total cells per lesion areas as described above.
Assessment of necrotic cores, smooth muscles, and collagen
Necrotic core areas, content of smooth muscle and collagen in atherosclerotic lesions, were measured as described. 1 Briefly, Optimas software was used to measure necrotic core areas defined as acellular areas of H&E-stained sections. Smooth muscle content in atherosclerotic lesions was assessed by staining with anti-a-actin antibody (BD Biosciences). To assess collagen contents, a polarized microscope was used to identify birefringent collagen from picrosirus red-stained atherosclerotic sections.
Total RNA extraction
Snap-frozen samples of spleens and aortic arches were processed to extract total RNAs using the RNeasy Mini kit (#74104, Qiagen, Hilden, Germany) and the RNeasy fibrous tissue Mini kit (#74704, Qiagen), respectively, as instructed by the manufacturer. On-column DNAase treatment in the RNA extraction procedure was performed as per manufacturer's recommendation to eliminate genomic DNA contamination. Quantity and quality of extracted RNA were determined by Nanodrop 2000C spectrophotometer (Thermo Scientific, Waltham, MA, USA).
Assessment of mRNA IFNg expression
One-step RT-PCR kit (#210215, Qiagen) was utilized to determine splenic and arterial mRNA expression of IFNg as described. 1 IFNg mRNA expression levels were analysed using the comparative cycle threshold method with 18S rRNA primers (Applied Biosystems Foster City, CA, USA).
Assessment of plasma IFNg
Plasma level of IFNg was determined by a commercial ELISA kit (#0002, Elisakit.com) as per manufacturer's instruction. Briefly, four-fold diluted plasma samples were incubated in wells pre-coated with mouse IFNg capture antibody. Subsequent incubation with biotin-labelled detection antibody was followed by freshly prepared streptavidin -HRP conjugate incubation. Colour developed by TMB substrate was stopped and optic density at 450 nm wavelength determined using a microplate reader. Plasma IFNg concentration was calculated using a standard curve provided and corrected by a dilution factor.
Plasma lipid analysis
Plasma lipids and cholesterols were determined as described. 1 
Statistical analysis
Graphad Prism (ver. 5.0) was used to analyse the data. Two-tailed unpaired Student's t-test (to compare two groups) and one-way analysis of variance with Dunnett's post hoc test comparing with the PBS-injected group (to compare three groups) were used to calculate statistical significance and a value of P , 0.05 was statistically considered significant.
Results

Chronic DPPE-PEG 350 treatment does not alter NKT and other lymphocytes
Mice were injected with DPPE-PEG 350 for a total of 16 times over 8 weeks. First, we asked whether chronic treatment of DPPE-PEG 350 affects NKT cell population in lipid-induced atherosclerosis. As NKT cells are predominantly found in liver parenchyma, 17 we determined liver-resident NKT cell population in mice that received DPPE-PEG 350 treatment at the end of 8-week HFD. FACS-assisted analysis of liver lymphocytes showed that NK1.1 + TCRb + NKT cells did not differ between treated and control mice ( Figure 1A) . DPPE-PEG 350 treatment also did not affect populations of CD4 + and CD8 + T cells, B cells, and NK cells ( Figure 1B ).
DPPE-PEG 350 treatment reduces the development of atherosclerosis
Next, we investigated whether DPPE-PEG 350 affects plasma lipid levels and atherosclerosis development. DPPE-PEG 350 -treated mice showed reduced body weight at the end of 8-week HFD ( Figure 1C) . Despite 10% reduction of body weight, DPPE-PEG 350 did not affect plasma lipids ( Figure 1D) . However, the development of lipid-induced atherosclerosis was significantly reduced in treated mice compared with the control group. Total intimal atherosclerotic lesion size and OROstained lipid accumulation were reduced by 45 and 52%, respectively, in ApoE 2/2 mice that received DPPE-PEG 350 treatment compared with the PBS group ( Figure 1E-G) . But, the ratio of lipid accumulation relative to intima area was similar (see Supplementary material online, Figure S1A ). (Figure 2A and B) , CD4 + and CD8 + T cells by 54% ( Figure 2C and D) and 94% ( Figure 2E and F) , respectively, and CD19 + B cell accumulation by 80% ( Figure 2G and H Figure 3A and B) and 57% ( Figure 3C and D) , respectively, in mice that received DPPE-PEG 350 compared with the control group. Collectively, our results suggest that reduced MCP-1 and VCAM-1 in atherosclerotic lesions may contribute to the reduced recruitment of macrophages, T cells, and B cells into lesion areas.
Reduced necrotic core accompanies reduced lesions of developing atherosclerotic lesions
As formation of necrotic cores in atherosclerotic lesions indicates progressive inflammation of atherosclerosis 36 and is a key feature of vulnerable atherosclerotic plaques 3 and is at least in part mediated by iNKT cells, 28 we next investigated the size of necrotic cores in atherosclerotic lesions of mice that received DPPE-PEG 350 compared with the vehicle control group. Defined by acellular areas in H&E-stained atherosclerotic lesions, DPPE-PEG 350 reduced necrotic core areas by 64% in hyperlidaemic ApoE 2/2 mice ( Figure 3E and F) . In contrast, DPPE-PEG 350 did not affect smooth muscle and collagen content in atherosclerotic lesions in mice with established atherosclerosis when aortic atherosclerotic lesions were immunohistochemically stained with anti-smooth muscle antibody and histologically stained with Picrosirius red ( Figure 3G -J).
DPPE-PEG 350 treatment retards progression of established atherosclerosis
After establishing that DPPE-PEG 350 decreases the development of atherosclerosis, we investigated whether DPPE-PEG 350 will also similarly retard established atherosclerotic lesions, because this approach will test the therapeutic potential of chronically inhibiting iNKT cell activation to treat patients with established atherosclerosis. ApoE
mice were first fed a HFD for 6 weeks to generate lipid-induced atherosclerosis, followed by DPPE-PEG 350 treatment as described above for a further 6 weeks while the mice were continued to be fed a HFD. With comparable body weight and plasma lipid profiles (data not shown), DPPE-PEG 350 treatment reduced atherosclerosis by 49% when assessed by total intimal lesion areas ( Figure 4A and B). Mice that received DPPE-PEG 350 treatment also reduced lipid accumulation in aortic sinus lesions by 27% ( Figure 4C ), demonstrating the potent pharmacological action of DPPE-PEG 350 in treating established atherosclerosis, but the ratio of lipid accumulation to intima area was unaffected (see Supplementary material online, Figure S1B ). Immunohistochemical staining of atherosclerotic lesions also showed that the numbers of CD68 + macrophages, CD4 + , CD8 + T cells, and CD19 + B cells in atherosclerotic lesions were reduced in mice with established atherosclerosis after treatment with DPPE-PEG 350 ( Figure 4D -G) . Similar to findings in the development of atherosclerosis, DPPE-PEG 350 reduced necrotic cores by 59% in established atherosclerotic lesions ( Figure 4H ), but it did not affect smooth muscle and collagen content ( Figure 4I and J).
DPPE-PEG 350 treatment reduces apoptotic cells in atherosclerotic lesions
NKT cells promote apoptosis in atherosclerotic lesions via by perforinand granzyme B-dependent mechanism. 28 Our data in the present study show that DPPE-PEG 350 treatment reduces necrotic core areas in developing and established lesions, suggesting reduced NKTgenerated apoptosis. Assessment of apoptotic cells in developed atherosclerotic lesions by TUNEL assay confirms that DPPE-PEG 350 treatment decreases apoptotic cells in established atherosclerosis ( Figure 5A and B) . Next, we investigated the cellular targets of apoptosis using IF staining of the lesion. We found that macrophages, not smooth muscle or endothelial cells, were a major target of apoptosis that were reduced by DPPE-PEG 350 treatment ( Figure 5C and Supplementary material online, Figure S2A and B). Continuity of plaque endothelial cells assessed by IF staining was not affected by DPPE-PEG 350 ( Figure 5D ), indicating that endothelial cells are not targeted by NKT cell-generated apoptosis.
DPPE-PEG 350 does not affect mRNA expression and plasma level of inflammatory cytokine IFNg
To determine the effect of DPPE-PEG 350 on production of IFNg as activated NKT cells secrete a large amount of IFNg, 25, 29 we first assessed IFNg mRNA expression in arterial arches and spleens using quantitative real-time PCR and also determined plasma IFNg level by ELISA. Control and treated ApoE 2/2 mice did not show any difference in IFNg mRNA expression in arterial and spleen tissues ( Figure 6A and B) . DPPE-PEG 350 -treated mice also showed similar levels of plasma IFNg compared with control mice (Figure 6C and D 24 ( Figure 7A and B) . In contrast, aGalCer-aggravated DPPE-PEG 350 reduces atherosclerosis development and progression atherosclerosis was completely abrogated by DPPE-PEG 350 treatment ( Figure 7A and B) . A similar finding was observed with ORO-stained lipid accumulation ( Figure 7C) ; however, lipid contents adjusted to lesion area were similar (data not shown). FACS analysis of liver lymphocytes showed that aGalCer injection reduced CD1d-tetramer + iNKT cells ( Figure 7D and E). 
Discussion
Our results showed that the CD1d-dependent lipid NKT antagonist, DPPE-PEG 350 , reduces both the development and progression of atherosclerosis induced by hyperlipidaemia. Our finding of significant reductions in atherosclerotic necrotic cores following DPPE-PEG 350 treatment is consistent with the cytotoxic actions of NKT cells augmenting inflammation as well as the development/progression of atherosclerosis. 28 In a pulmonary alveolitis mouse model, a single dose of DPPE-PEG 350 is sufficient to prevent aGalCer-augmented inflammation, indicating a DPPE-PEG 350 reduces atherosclerosis development and progression potent anti-inflammatory effect of DPPE-PEG 350 in NKT-aggravated immune responses. 29 Here, we showed that long-term treatment with the CD1d-dependent lipid antagonist DPPE-PEG 350 over 8 weeks reduced atherosclerosis development. Importantly, 6-week treatment of DPPE-PEG 350 also delayed the progression of atherosclerosis established by feeding a HFD for 6 weeks. While plasma lipids were unaffected in both experiments, DPPE-PEG 350 -treated mice showed a small reduction in body weight in atherosclerosis development (prevention experiment). It is possible that the small reduction in body weight is due to DPPE being partially metabolized in vivo by phosphatidylethanolamine N-acyltransferase to generate N-arachidonyl-DPPE and N-acylphosphatidylethanolamines; 37 N-acylphosphatidylethanolamines that are also produced by the small intestine can suppress food intake. 38 Our findings suggest a therapeutic potential of NKT-targeted CD1d-dependent antagonist approach to control inflammation in the management of patients with atherosclerosis. The reduced atherosclerosis in both development and progression was not associated with plasma lipid levels, suggesting a direct effect on iNKT cells, most likely by DPPE-PEG 350 competing with lipid antigen for binding to the CD1d molecule on antigen-presenting cells. The suggestion is consistent with the observation that PEG-conjugated DPPE maximally inhibited oxazolone-induced dermatitis when included during priming and challenge. 30 Therefore, molecules, such as DPPE-PEG 350 , may be suitable to prevent lipid antigen presentation by CD1d to NKT cells in the treatment of NKT cell-mediated inflammatory disorders including atherosclerosis.
NKT cells representing at 0.5 -2.5% of T cells in blood, spleens, and lymph nodes are found mainly in liver where they comprise up to 30% of T cells in liver sinusoids. 16, 17 Analysis of liver lymphocytes showed no difference in both NKT and other lymphocyte profiles between treated and untreated groups, suggesting that DPPE-PEG 350 treatment have no effect on lymphocyte populations. Our results are in accordance with earlier observation where expression of Va14Ja18 (NKT TCR) transcripts were uniformly found before and many days after chemical challenge, indicative of the importance in NKT cell activation, in NKT cell-augmented inflammation. 30 When NKT agonist, aGalCer, was given to ApoE 2/ 2 mice, CD1d-competent mice recruited more T cells (either CD3 + or TCRb + ) into atherosclerotic lesions. 24, 25 Recruitment of immune cells in allergen-induced alveolitis and dermatitis was dramatically ameliorated by the treatment of PEG-conjugated DPPE. 29, 30 These findings suggest an important role of activated NKT cells in recruitment of immune cells into inflammatory sites. In our study, the numbers of lesion CD4 + and CD8 + T cells were decreased in atherosclerotic lesions when NKT cell activation was prevented by DPPE-PEG 350 , confirming that prevention of NKT cell activation by NKT cell antagonist reduces immune cells in atherosclerotic lesions. Our finding that lesion B cell numbers were also reduced is consistent with iNKT cells enhancing B cell responses. Recruitment of immune cells is associated with expression of adhesion molecules and leucocyte-attractant proteins. In addition to stimulating homing of monocytes, MCP-1 can also direct migration of B and T cells to inflammatory sites. 40 VCAM-1 is also important for induction of T cell antigen receptor-dependent activation CD4 + T cells. 41 25 and most likely to contribute to the observed reductions in macrophage accumulation within atherosclerotic lesions. Previously, we have shown that iNKT cells influence lesion collagen levels, 23 but in the present study lesion collagen levels were unaffected by DPPE-PEG 350 treatment. One possible explanation for this difference is that collagen levels are more influenced by mechanisms other DPPE-PEG 350 reduces atherosclerosis development and progression than lipid antigen presentation to iNKT cells during the development of atherosclerosis. Recently, it has been shown that peptides may also activate CD1d-restricted NKT cells. 43 It is possible that such activation is not prevented by DPPE-PEG 350 . The mechanisms by which iNKT cells influence lesion collagen are yet to be determined, but appear independent on lesion vascular smooth muscle cell numbers. In early development of atherosclerosis, macrophage apoptosis and efficient efferocytosis suppress fatty streak development/progression. 44, 45 As atherosclerosis progresses to atheromatous (Type IV) lesions and beyond, 46 more cells, including smooth muscles and/or immune cells mostly macrophages, undergo apoptosis 44 and clearance of apoptotic cells becomes impaired, 45 leading to post-apoptotic necrosis and necrotic core development and accelerated sterile inflammation in atherosclerotic lesions. 47 Enlargement of necrotic cores is a key feature of vulnerable plaques. 3 Our finding that lesion smooth muscle content was unaffected in CD1d-dependent NKT antagonisttreated mice suggests that reduced lesion necrosis is mainly due to reduced macrophage post-apoptotic necrosis. The data are consistent with our recent report that NKT cells are able to promote atherosclerosis by perforin-and granzyme B-dependent cytotoxicity that results in apoptosis and generation of necrotic cores in atherosclerotic lesions. 28 IFNg expression in DPPE-PEG 350 -treated mice that did not differ from the control group indicates that the NKT cell antagonist does not affect IFNg expression after 8 weeks of treatment. The reduction in inflammation induced by DPPE-PEG 350 is most likely, at least in part, the consequence of the reduced post-apoptotic necrosis, given that cell necrosis initiates inflammatory responses including inflammasome activation 48 that leads to production of molecules such as MCP-1. 49 Necrotic cells also release damage-associated molecular patterns (DAMPs) that drive inflammation. 50 Endogenous DAMPs, such as high mobility group box 1 protein (HMGB1), biglycans, heat shock proteins, heparan sulfate, SA100A8/A9, and fibrinogen, are responsible for sterile inflammation in atherosclerosis. 51, 52 We have previously shown that one such DAMP, HMGB1, augments the development of atherosclerosis. 53 Apoptosis-and post-apoptotic necrosis-derived proteins are present at every stage during atherosclerosis pathogenesis. 54 Given the important roles of necrotic cells in atherosclerosis, targeting post-apoptotic cell necrosis with an agent such as the CD1d-dependent lipid antagonist might be a more efficacious pharmacological approach to control inflammation in atherosclerosis than targeting individual DAMPs. DPPE-PEG 350 prevents iNKT cell effector function by blocking CD1-dependent lipid antigen presentation, 29, 30 and inhibits glycolipidinduced CD1d-dependent cytokine production from monocytes. 55 The observation that aGalCer increased atherosclerosis was totally prevented by prior treatment with DPPE-PEG 350 confirms CD1d-dependent atheroprotective effect of DPPE-PEG 350 treatment. However, iNKT cells detected in liver were very low in aGalCer-injected mice and our finding is consistent with down-regulated TCR expression in iNKT cells that requires several days to reach normal expression. 56 Several lines of evidence indicate that NKT cell/CD1d + antigenpresenting cell interactions are also important for progression of atherosclerotic lesions in humans. NKT cells and CD1d-expressing antigen-presenting cells are present in human atherosclerotic plaques. 22, 57 CD1d + cells are abundant in advanced human neovascularized lesions, 22 suggesting an important role for NKT cells activated by CD1d-mediated lipid antigen presentation in promoting vulnerable plaque formation. NKT cells isolated from human plaques showed increased inflammatory responses when stimulated with aGalCer in culture. 22 Proinflammatory lysophospholipids, lysophosphatidylcholine, and plasmalogen lysophosphatidylethanolamine are known lipid antigens for human NKT cells. 58 The observation that DPPE-PEG 350 completely abrogates aGalCer-induced aggravated atherosclerosis suggests a possible therapeutic approach to limit NKT cell activation in human atherosclerosis. In summary, we have shown that targeting NKT cells during the development of atherosclerosis as well as the progression of established atherosclerosis with CD1d-dependent lipid antagonist effectively ameliorates atherosclerosis in hyperlipidaemic ApoE 2/2 mice by preventing accumulation of necrotic cells/debris and associated inflammation. Our findings suggest that such targeting using agents, such as DPPE-PEG, in combination with anti-hyperlipidaemic agents may further improve clinical outcomes in atherosclerosis.
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